LES Royalty Rates and Deal Terms Surveys

Global BioPharma Royalty Rates and Deal Terms Survey

2012 Survey Highlights

• A total of 120 completed surveys were incorporated into the final Global BioPharma Survey Report. 
• Of those who responded, 31% were from pharmaceutical companies, 22% were from biotech companies, 9% were from academic institutions, 6% were from government, and 32% were from other organizations.
• The survey covered assets at all stages of development and the report offers a wealth of information on early stage programs. In all, 24% of the deals addressed assets in the discovery phase and another 16% covered programs that were on an IND track but had not yet been filed. 
• Approximately 65% of the deals were considered “Global” in scope.
• The survey covered assets at all stages of development and the report offers a wealth of information on early stage programs. In all, 24% of the deals addressed assets in the discovery phase and another 16% covered programs that were on an IND track but had not yet been filed. 

Read the press release here. The full survey is available to members only here. 

Click here to access information regarding the 2009 Global BioPharma Royalty Rates and Deal Terms Survey.

Click here to access information regarding the 2008 Global BioPharma Royalty Rates and Deal Terms Survey.

High Tech Sector Royalty Rate & Deal Terms Survey 

2011 Survey Highlights

• The Survey received responses from 52 companies for the period from 2008 through 2011, with a total of 228 complete deals being submitted.  
• The following major high technology fields were reported: aerospace, software, clean technology, communication, semiconductor, consumer products and electronics. 
• 86% of respondents were licensors, with more than half of them entering the deal for monetary gain in addition to a strategic relationship.

Click here for an executive summary of the survey. The full survey is available to LES members, so please login for access.

Chemicals, Energy, Environmental and Materials (CEEM) Royalty Rates & Deal Terms Survey

2010 Survey Highlights

• Survey participation included academic institutions (34%), operating companies that ranged from big energy to start-up (39%), lawyers (16%), and other licensing organizations (11%). 
• Approximately 70% of the deals collected contained flat running royalties and most deals were entered by the licensor. About 75% of the deals were executed during 2008 or 2009 and 80% of the deals came from the chemicals and energy sectors. 
• Of those reported, approximately 40% of the deals estimated peak annual sales of less than $50 million, most deals involved commercialized or soon to be commercialized products/technologies and a majority of the deals were exclusive.

Click here for an executive summary of the survey. The full survey is available to LES members, so please login for access.